Umeclidinium/Vilanterol 62.5/25 mcg
Sponsors
GlaxoSmithKline
Conditions
Pulmonary Disease, Chronic Obstructive
Phase 3
Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg
CompletedNCT01716520
Start: 2012-10-31End: 2013-03-31Updated: 2017-01-09
The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD
CompletedNCT01777334
Start: 2013-01-23End: 2013-09-24Updated: 2018-01-24
The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium
CompletedNCT01899742
Start: 2014-09-15End: 2015-07-22Updated: 2018-01-24
A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT02014480
Start: 2013-02-01End: 2013-06-11Updated: 2018-02-15